Towards a Cure for HIV: 
From Pathogenesis to Eradication 

September 5–6, 2013 | Nobel Forum, Karolinska Institutet, Stockholm
Organized by the Centre for HIV Research at Karolinska Institutet
THURSDAY SEPTEMBER 5 2013, NOBEL FORUM, KAROLINSKA INSTITUTET STOCKHOLM | 09.00–16.20

08.20–09.00  Registration
09.00–09.10  Introduction by Johan Sandberg and Francesca Chiodi
09.10–09.40  Steven Deeks, University of California, San Francisco
Keynote address: Towards an HIV cure

Session I  Novel insights in immunopathogenesis
Chairs: Kristina Broliden and Johan Sandberg

09.40–10.10  Merlin Robb, US Military HIV Research Program, Silver Spring:
Findings in the ECHO (RV217) study of acute HIV infection

10.10–10.40  Coffee break

10.40–11.10  Nilu Goonetilleke, Oxford University, Oxford: Immune responses in acute infection
11.10–11.30  Edwin Leansyah, Karolinska Institutet, Stockholm, Short talk:
Will loss of your MAITs weaken your HAART?
11.30–12.00  Mario Ostrowski, University of Toronto, Toronto:
Targeting Human Endogenous Retroelements as an HIV Vaccine strategy

12.00–12.50  Lunch break

12.50–13.00  Welcome address by Anders Hamsten, President of Karolinska Institutet
13.00–13.30  Teunis Geijtenbeek, University of Amsterdam, Amsterdam:
Dendritic cells in HIV immunopathogenesis

Session II  Approaches to immune-modulation and a functional cure
Chairs: Francesca Chiodi and Anna Mia Ekström

13.30–14.00  Brigitte Autran, Pierre and Marie Curie University, Paris:
Elite controllers as a model of functional cure
14.00–14.30  Ivona Pandrea, University of Pittsburgh, Pittsburgh:
Testing the role of microbial translocation in SIV immunopathogenesis
14.30–15.00  Kehmia Titanji, Emory Vaccine Center, Emory University School of Medicine, Atlanta:
Bone disease in HIV infection

15.10–15.30  Coffee break

15.30–16.00  Hanneke Schuitemaker, University of Amsterdam, Amsterdam, and Crucell Holland B.V.:
A role for HIV neutralizing antibodies in a functional HIV cure?
16.00–16.20  Marianne Jansson, Lund University, Lund, Short talk:
HIV-2 immunity, model of viral control and functional cure

18.30  Conference dinner
## Session III  
**Drug discovery and development**  
*Chairs: Anders Sönnerborg and Anna Karlsson*

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Institution</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00–09.30</td>
<td>Guido Vanham</td>
<td>Institute for Tropical Medicine, Antwerpen</td>
<td>CHAARM</td>
</tr>
<tr>
<td>09.30–10.00</td>
<td>Jan Balzarini</td>
<td>Rega Institute for Medical Research, Leuven</td>
<td>Carbohydrate-binding agents as multi-functional and multi-targeting chemotherapeutics</td>
</tr>
</tbody>
</table>

### 09.00–10.30  
**Coffee break**

## Session IV  
**Latency, reactivation and translation into clinical studies**  
*Chairs: Jan Albert and Markus Moll*

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Institution</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.30–11.00</td>
<td>Robert Siliciano</td>
<td>Johns Hopkins University, Baltimore</td>
<td>Detection and elimination of latently infected cells</td>
</tr>
<tr>
<td>11.00–11.30</td>
<td>Sarah Palmer</td>
<td>Westmead Millennium Institute/University of Sydney/Karolinska Institutet</td>
<td>Characterizing the Latent HIV Reservoir</td>
</tr>
<tr>
<td>11.30–12.00</td>
<td>Sharon Lewin</td>
<td>Monash University, Melbourne</td>
<td>Activating latent HIV using histone deacetylase inhibitors</td>
</tr>
</tbody>
</table>

### 10.00–12.00  
**Lunch**

### 13.00–14.00  
<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Institution</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.00–13.30</td>
<td>David Margolis</td>
<td>University of North Carolina, Chapel Hill</td>
<td>Disrupting latency</td>
</tr>
<tr>
<td>13.30–14.00</td>
<td>Michael Miller</td>
<td>Merck Research Laboratories, West Point</td>
<td>Farnesyl transferase inhibitors synergize with other compounds to reserve HIV-1 latency</td>
</tr>
</tbody>
</table>

## Session V  
**Cell therapy, gene therapy and therapeutic vaccines**  
*Chairs: Anna-Lena Spetz and Marianne Jansson*

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Institution</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00–14.30</td>
<td>Jim Riley</td>
<td>University of Pennsylvania, Philadelphia</td>
<td>Gene therapy approaches to treat and cure HIV-1 infection</td>
</tr>
</tbody>
</table>

### 14.30–15.00  
**Coffee break**

### 15.00–15.30  
<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Institution</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.00–15.30</td>
<td>Yves Levy</td>
<td>Vaccine Research Institute, Paris</td>
<td>DC-based prophylactic and therapeutic vaccines in HIV</td>
</tr>
<tr>
<td>15.30–15.50</td>
<td>Viktor Dahl</td>
<td>Karolinska Institutet, Stockholm, Short talk</td>
<td>Is the CNS a reservoir?</td>
</tr>
<tr>
<td>15.50–16.20</td>
<td>Christine Rouzioux</td>
<td>Paris Descartes University, Paris</td>
<td>VISCONTI study: An example of functional cure?</td>
</tr>
</tbody>
</table>

### 16.20  
**Final words by Anna-Lena Spetz and Anders Sönnerborg**